Dosing: Altered kidney function
No kidney-specific text is available from the US label for this generic yet. Check the Philippine package insert in the products table.
Kidney-specific guidance from renalcarematters.com: in preparation.
Dosage forms
Philippines
- ) powder for solution for infusion: 500 Units/10 mL (50 Units/mL, 1000 U/20 mL (50 U/mL
Registered products in the Philippines
2 products registered with the Food and Drug Administration (FDA) Philippines list Factor viii inhibitor bypassing activity as the generic name. Registration status changes; confirm a product's current status on the FDA portal before relying on it.
| Package insert | |||||||
|---|---|---|---|---|---|---|---|
FeibaFactor VIII Inhibitor Bypassing Activity | 1000 U/20 mL (50 U/mL) Powder for Solution for Infusion (IV)500, 1000, and 2500 units (U) per vial supplied with a diluent in a vial containing steril water for injection | Rx | Baxter AGAustria | Takeda Healthcare Philippines Inc. | BR-1443 | Jun 19, 2028 | |
Feiba: Factor VIII Inhibitor Bypassing Activity | 500 Units/10 mL (50 Units/mL) Powder for Solution for Infusion (IV)Packaging: Each box contains: Type I clear and colorless glass vial with grey butyl rubber stopper and aluminum crimp cap with polypropylene flip-off disk (drug product) + Type I clear glass vial with bromobutyl rubber stopper and aluminum seal plastic flip-off cap (Sterile Water for Injection as diluent) + Twin set butterfly needle 22G (Venofix) and cannula 20G (Sterican) + Sterile needleless transfer device for reconstitution (Baxter II Hi-Flow) + Disposable syringe with luer lock (Omnifix). | Rx | Baxter AGAustria | Takeda Healthcare Philippines Inc. | BR-1438 | Feb 8, 2028 |
Source: FDA Philippines product registration database. "Valid until" is the registration validity date listed by the FDA; a past date may mean a renewal is pending. Package insert links point to files published by the FDA.
Formulary and pricing (Philippines)
Formulary and coverage
| Philippine National Formulary | Listed as Factor VIII Inhibitor Bypassing Activity |
| PNF listing | Solution for infusion (IV), 500 IU/10 mL |
| PNF listing | Solution for infusion (IV), 1,000 IU/10 mL |
| PNF listing | Solution for infusion (IV), 2,500 units/50 mL |
| PhilHealth GAMOT | No |
Sources:
- PhilHealth Advisory No. 2025-0060, Electronic PNF EML (ePNF) as of September 19, 2025, annex of added medicines; DOH-DC No. 2025-0341 (included 2025-08-11); https://www.philhealth.gov.ph/advisories/2025/PA2025-0060_v1.pdf, as of August 11, 2025
Check availability
Prices and stock vary by branch; renalcarematters.com does not sell medicines or receive payment from pharmacies.
References
- Food and Drug Administration Philippines. Verification portal (product registrations). https://verification.fda.gov.ph
- PhilHealth Advisory No. 2025-0060, Electronic PNF EML (ePNF) as of September 19, 2025, annex of added medicines; DOH-DC No. 2025-0341 (included 2025-08-11); https://www.philhealth.gov.ph/advisories/2025/PA2025-0060_v1.pdf
This page shows official label and registry text only; no renalcarematters.com clinical summary has been approved for it yet.
Last updated: .